Surgical Deroofing in HS: How, When, and Why?

March 14, 2025

New Dosing Option for UCB’s Bimekizumab Now Commercially Available for PsO, PsA, and HS Patients

January 16, 2025

A Future Dermatologist’s Journey With HS

December 2, 2024

Expert Perspective: What Does the Approval of Bimekizumab-bkzx (Bimzelx, UCB) Mean for The HS Community?

November 22, 2024

U.S. FDA Gives Its Nod to Bimekizumab-bkzx (Bimzelx, UCB) for HS

November 20, 2024

Does Semaglutide Improve Outcomes for Obese Patients With HS?

September 24, 2024

The Patient Perspective: How to Build a Rapport With HS Patients

August 29, 2024

Treating HS in 2024 and Beyond

August 26, 2024

UCB Launches ‘Make HStory’ Campaign for People Living with HS and Their Doctors

April 11, 2024

MoonLake, Komodo Health Partner to Study Inflammatory Skin and Joint Conditions

April 10, 2024

FDA Accepts sBLA for UCB’s Bimzelx in Moderate-to-Severe HS and Additional 2mL Device Presentations

April 4, 2024

News You Can Use: AARS Now Accepting Applications for Research Grant Awards

March 13, 2024